Home > Boards > US Listed > Biotechs > Halozyme Therapeutics (HALO)

I think it's fair to say that the

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Fred Kadiddlehopper Member Profile
 
Followed By 24
Posts 3,456
Boards Moderated 1
Alias Born 09/22/06
160x600 placeholder
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/1/2019 7:11:11 PM
Halozyme To Participate In 2019 Cantor Global Healthcare Conference PR Newswire (US) - 9/23/2019 8:00:00 AM
Positive Results Announced From Phase 3 Trial Evaluating Fixed-Dose Subcutaneous Combination Of Perjeta® And Herceptin® Usi... PR Newswire (US) - 9/13/2019 1:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/4/2019 11:21:22 AM
Halozyme To Participate In 2019 Wells Fargo Healthcare Conference PR Newswire (US) - 8/26/2019 8:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/6/2019 4:19:53 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/6/2019 4:13:31 PM
Halozyme Reports Second Quarter 2019 Results PR Newswire (US) - 8/6/2019 4:01:00 PM
Halozyme To Participate In 39th Annual Canaccord Genuity Growth Conference PR Newswire (US) - 7/25/2019 8:00:00 AM
Halozyme To Host Second Quarter 2019 Financial Results Webcast And Conference Call PR Newswire (US) - 7/23/2019 4:01:00 PM
J&J's Janssen Seeks Europe OK For Subcutaneous Darzalex in Multiple Myeloma Dow Jones News - 7/19/2019 7:45:00 AM
Halozyme Announces Janssen Submits Extension Application To European Medicines Agency For Subcutaneous Formulation Of DARZALE... PR Newswire (US) - 7/19/2019 7:00:00 AM
Halozyme Announces First Clinical Dosing In argenx's Phase 1 Trial Of Efgartigimod (ARGX-113) With ENHANZE® Drug Delivery Te... PR Newswire (US) - 7/17/2019 8:00:00 AM
Halozyme Announces Janssen Submits BLA To FDA For Subcutaneous Formulation Of DARZALEX® Utilizing ENHANZE® Technology PR Newswire (US) - 7/12/2019 11:59:00 AM
Amended Statement of Beneficial Ownership (sc 13d/a) Edgar (US Regulatory) - 7/3/2019 4:02:19 PM
Halozyme Announces CRADA With National Institute of Allergy and Infectious Diseases For Use Of ENHANZE® Drug Delivery Techno... PR Newswire (US) - 6/25/2019 8:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/17/2019 8:20:11 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/12/2019 1:41:16 PM
Amended Statement of Beneficial Ownership (sc 13d/a) Edgar (US Regulatory) - 6/7/2019 5:11:39 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/4/2019 4:45:58 PM
Halozyme To Participate In Upcoming Investor Conferences PR Newswire (US) - 6/4/2019 8:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/3/2019 5:24:28 PM
Halozyme Announces argenx Has Selected Second Target Under ENHANZE® Technology Collaboration And License Agreement PR Newswire (US) - 5/22/2019 1:05:00 AM
Post-effective Amendment to an S-8 Filing (s-8 Pos) Edgar (US Regulatory) - 5/14/2019 5:11:52 PM
Post-effective Amendment to an S-8 Filing (s-8 Pos) Edgar (US Regulatory) - 5/14/2019 5:08:35 PM
Fred Kadiddlehopper   Thursday, 01/31/19 08:01:19 PM
Re: maumar post# 5576
Post # of 5693 
I think it's fair to say that the next six months are going to be quite interesting.
-Fritz

The more you know, the less you don't know.
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist